Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:45:48.404Z.
Calculation as of: 2026-10-06T19:45:48.404Z.
Quote observation: 2026-10-06T19:45:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$711.21M
PE Ratio
N/A
TTM Avg
359.25
3Y Avg
359.25
5Y Avg
359.25
Market Cap
$761.35M
PE Ratio
161.97
TTM Avg
129.79
3Y Avg
309.15
5Y Avg
358.87
Market Cap
$710.66M
PE Ratio
17.67
TTM Avg
23.33
3Y Avg
39.10
5Y Avg
32.90
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $745.49M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $736.99M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $724.64M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.40M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $755.18M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $711.21M | N/A | 359.25 | 359.25 | 359.25 |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.35M | 161.97 | 129.79 | 309.15 | 358.87 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $710.66M | 17.67 | 23.33 | 39.10 | 32.90 |
| Sana Biotechnology, Inc. (SANA)vs › | $772.26M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $700.60M | N/A | 991.02 | 502.52 | 502.52 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
